Novadip Biosciences shows the ambition to grow to a worldwide class. The Belgian-based biotech company recently announced the closing of a €28 million Series A financing to advance breakthrough cell therapy pipeline with its lead compound Creost ®.
This growth leads to an expansion of Novadip’s research and development goals – and an expected increase in hiring. Jean-François Pollet, CEO and co-founder of Novadip said « The proceeds will be used to advance clinical development of Creost and realize its full potential as a first-in-class medicinal product with broad applicability in bone reconstruction. »
We are delighted to announce that PaHRtners starts a strategic collaboration with Novadip Biosciences, a leader in first-in-class treatments for bone reconstruction. We are actively looking for candidates eager to join this high-potential innovative company. All jobs are based in the Brussels area (Louvain-la-Neuve), in an English-speaking work environment.
PaHRtners is already searching for a Director Clinical Development who will be responsible for the company’s novel regenerative medicines development and registration:
As a Director Clinical Development, you are responsible for the company’s novel regenerative medicines development and registration. Reporting to the CEO, you strategically lead the clinical operations in a matrix organisation. With regards to resources and results, you efficiently manage the clinical team.